

Velcade (bortezomib): Starting Dose Adjustments for Patients with Hepatic Impairment

FDA MedWatch

Patients with moderate or severe hepatic impairment should be treated with reduced starting doses and closely monitored.

[SOURCE](#) [1]

Source URL (retrieved on 01/27/2015 - 10:17am):

<http://www.ecnmag.com/news/2010/01/velcade-bortezomib-starting-dose-adjustments-patients-hepatic-impairment>

Links:

[1] <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198424.htm>